Skip to main content

Table 2 Overall and stratified meta-analyses of the association between the EPHX1 His139Arg polymorphism and cancer risk

From: Quantitative assessment of the influence of EPHX1 gene polymorphisms and cancer risk: a meta-analysis with 94,213 subjects

Variables Noa Case/control Homozygote comparison Heterozygote comparison Dominant model Recessive model Additive model
    OR (95% CI) P Pb(I2) OR (95% CI) P Pb(I2) OR (95% CI) P Pb(I2) OR (95% CI) P Pb(I2) OR (95% CI) P Pb(I2)
Total 54 19437/27289 1.05(0.93 ~ 1.18) 0.73 0.09(21.3) 0.96(0.91 ~ 1.01) 0.15 0.02(31.5) 0.97(0.92 ~ 1.03) 0.30 0.00(40.1) 1.02(0.93 ~ 1.13) 0.66 0.23(12.0) 0.99(0.94 ~ 1.04) 0.57 0.00(44.9)
Cancer type                  
Other 11 3160/4581 0.94(0.75 ~ 1.20) 0.64 0.53(0.0) 0.97(0.87 ~ 1.10) 0.51 0.56(0.0) 0.97(0.87 ~ 1.06) 0.47 0.53(0.0) 0.96(0.76 ~ 1.21) 0.71 0.53(0.0) 0.97(0.89 ~ 1.05) 0.50 0.46(0.0)
Blood 9 2929/3629 0.87(0.67 ~ 1.13) 0.29 0.90(0.0) 0.90(0.81 ~ 1.00) 0.05 0.25(21.4) 0.90(0.81 ~ 0.99) 0.04 0.47(0.0) 0.90(0.70 ~ 1.17) 0.44 0.82(0.0) 0.91(0.83 ~ 0.99) 0.04 0.80(0.0)
Esophageal 3 593/1081 1.30(0.50 ~ 3.38) 0.59 0.07(61.8) 1.02(0.65 ~ 1.62) 0.92 0.03(72.6) 1.06(0.66 ~ 1.73) 0.80 0.01(77.3) 1.30(0.54 ~ 3.13) 0.56 0.10(56.5) 1.10(0.71 ~ 1.69) 0.67 0.01(79.2)
Colorectal 10 5552/7089 1.14(0.85 ~ 1.53) 0.39 0.02(53.5) 0.92(0.85 ~ 0.99) 0.03 0.97(0.0) 0.94(0.87 ~ 1.01) 0.09 0.73(0.0) 1.17(0.87 ~ 1.58) 0.29 0.02(54.0) 0.97(0.91 ~ 1.03) 0.28 0.11(36.8)
Lung 14 4767/8411 1.14(0.83 ~ 1.56) 0.42 0.02(49.3) 1.10(0.94 ~ 1.27) 0.24 0.00(63.4) 1.10(0.93 ~ 1.29) 0.27 0.00(71.9) 0.97(0.80 ~ 1.17) 0.76 0.16(27.2) 1.07(0.93 ~ 1.24) 0.36 0.00(74.1)
Head and neck 4 1035/1075 1.28(0.81 ~ 2.02) 0.30 0.99(0.0) 0.84(0.70 ~ 1.01) 0.06 0.69(0.0) 0.88(0.73 ~ 1.05) 0.14 0.70(0.0) 1.35(0.85 ~ 2.13) 0.20 1.0(0.0) 0.94(0.81 ~ 1.01) 0.41 0.78(0.0)
Breast cancer 3 1401/1423 1.04(0.69 ~ 1.59) 0.85 0.49(0.0) 0.91(0.77 ~ 1.07) 0.04 0.66(0.0) 0.92(0.79 ~ 1.08) 0.30 0.67(0.0) 1.09(0.93 ~ 1.13) 0.70 0.49(0.0) 0.95(0.83 ~ 1.09) 0.44 0.66(0.0)
Source of control                  
HB 16 5010/5638 1.14(0.93 ~ 1.41) 0.21 0.99(0.0) 0.96(0.88 ~ 1.05) 0.37 0.20(22.7) 0.98(0.90 ~ 1.06) 0.63 0.32(11.4) 1.17(0.95 ~ 1.44) 0.15 0.99(0.0) 1.00(0.94 ~ 1.08) 0.94 0.66(0.0)
PB 36 14191/21351 1.04(0.89 ~ 1.22) 0.61 0.01(39.4) 0.96(0.90 ~ 1.03) 0.22 0.01(39.4) 0.97(0.90 ~ 1.04) 0.40 0.00(50.7) 1.04(0.90 ~ 1.21) 0.56 0.05(30.0) 0.99(0.92 ~ 1.05) 0.64 0.00(57.2)
Ethnicity                  
Asian 13 2957/3770 0.97(0.75 ~ 1.27) 0.84 0.51(0.0) 0.99(0.89 ~ 1.11) 0.90 0.26(18.6) 0.99(0.89 ~ 1.10) 0.88 0.14(30.6) 0.98(0.76 ~ 1.28) 0.90 0.59(0.0) 1.01(0.90 ~ 1.13) 0.90 0.09(37.1)
Caucasian 32 12294/17831 1.10(0.93 ~ 1.30) 0.26 0.03(34.8) 0.95(0.88 ~ 1.02) 0.18 0.01(44.0) 0.97(0.89 ~ 1.04) 0.39 0.00(52.8) 1.07(0.95 ~ 1.21) 0.27 0.11(24.4) 0.99(0.92 ~ 1.06) 0.71 0.00(57.3)
Mixed 7 3921/5262 0.90(0.73 ~ 1.12) 0.35 0.81(0.0) 0.94(0.86 ~ 1.04) 0.22 0.43(0.0) 0.94(0.86 ~ 1.03) 0.16 0.69(0.0) 0.92(0.74 ~ 1.14) 0.45 0.71(0.0) 0.95(0.88 ~ 1.02) 0.15 0.93(0.0)
African 2 265/426 0.81(0.22 ~ 2.96) 0.75 0.08(21.3) 1.09(0.79 ~ 1.50) 0.60 0.78(0.0) 1.06(0.78 ~ 1.45) 0.69 0.46(0.0) 0.78(0.23 ~ 2.73) 0.70 0.08(66.6) 1.03(0.94 ~ 1.01) 0.84 0.22(34.7)
Smoking status                  
Smoker 9 2331/2542 1.08(0.64 ~ 1.83) 0.77 0.01(61.5) 1.19(0.88 ~ 1.60) 0.27 0.00(76.6) 1.16(0.85 ~ 1.58) 0.35 0.00(79.9) 1.04(0.68~1.60) 0.86 0.06(46.8) 1.09(0.84 ~ 1.41) 0.52 0.00(80.1)
Non-smoker 8 1498/2336 1.25(0.90 ~ 1.75) 0.19 0.67(0.0) 1.05(0.91 ~ 1.21) 0.49 0.78(0.0) 1.08(0.94 ~ 1.23) 0.30 0.71(0.0) 1.24(0.89 ~ 1.72) 0.21 0.71(0.0) 1.08(0.96 ~ 1.22) 0.19 0.60(0.0)
  1. PB: population based; HB: hospital based. Pb: P-values for heterogeneity from Q test; I2 refers to the proportion of total variation owing to between-study heterogeneity.
  2. Bold font marks where fixed effect model used.
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us